Fig. 2: Antibody prophylaxis against SARS-CoV-2 variants in K18-hACE2 mice.
From: In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
a–l, Eight-to-ten-week-old female and male K18-hACE2 transgenic mice received 40 μg (about 2 mg kg−1) of the indicated mAb treatment by intraperitoneal injection one day before intranasal inoculation with 103 FFU of the SARS-CoV-2 N501Y/D614G (a–c), B.1.1.7 (d–f), Wash-B.1.351 (g–i) or Wash-B.1.1.28 (j–l) strains. Tissues were collected at six days after infection. a, d, g, j, Weight change after infection with SARS-CoV-2 (mean ± s.e.m.; n = 6–12 mice per group, two experiments; one-way analysis of variance (ANOVA) with Dunnett’s test of area under the curve. NS, not significant; ****P < 0.0001). Viral RNA levels in the lung (b, e, h, k) and nasal washes (c, f, i, l) were measured (line indicates median; in order from left to right, n = 9, 6, 7, 6, 6 and 6 (a); n = 11, 5, 5, 6, 6 and 6 (b); n = 9, 5, 5, 6, 6 and 6 (c); n = 12, 6, 6, 6, 5 and 6 (d–f); n = 12, 6, 6, 6, 6 and 6 (g, h, j, k); n = 12, 6, 6, 6, 6 and 5 (i); n = 10, 6, 6, 6, 6 and 5 (l) mice per group, two experiments; one-way ANOVA with Dunnett’s test with comparison to control mAb. NS, not significant, ****P < 0.0001; *P = 0.026 (c); **P = 0.0016, ***P = 0.0002 (l)). Dotted line indicates the limit of detection of the assay.
